We measured the effect of low-level fluoroquinolone resistance in Streptococcus pneumoniae on the development of high-level resistance within the context of the mutant selection window.
may be required to preserve the utility of existing agents and to assure a long life span for new compounds.
One approach for restricting resistance is to avoid conditions that enrich resistant bacterial subpopulations [4, 5] . Such conditions have been defined in vitro for fluoroquinolones with a variety of bacteria. In general, fluoroquinolone-resistant mutants are enriched when drug concentrations fall within a range called the mutant selection window [4] . The lower boundary of the window is approximated by the MIC 99 , the minimal concentration that blocks growth of 99% of the cells in a culture. The upper boundary is the MIC of the least-susceptible single-step mutant, a value called the mutant prevention concentration (MPC), because, above this concentration, 2 concurrent resistance mutations must be acquired for growth. Conditions that expand the selection window, such as the acquisition of a low-level parC (DNA topoisomerase IV) resistance allele by S. pneumoniae, are expected to facilitate the enrichment and amplification of high-level resistant mutants, because bacterial exposure to the antimicrobial agent will be inside the window longer [6] . Moreover, quinolone lethality is expected to be lower [6] , and the frequency at which gyrase mutants are enriched will be higher [6, 7] . The present work shows that predictions based on in vitro observations apply in an animal model, which supports the approach of evaluating chemotherapies for antimutant activity and emphasizes the importance of halting the development of low-level resistance.
Materials and methods. S. pneumoniae (serotype 9V) strains included a fluoroquinolone-susceptible, penicillin-resistant clinical isolate (16089) and 2 laboratory derivatives selected by exposure to ciprofloxacin-strain MS1A, a reserpine-sensitive efflux strain, and MR3B4, a parC Ser-79 to Tyr variant [8] . S. pneumoniae was grown at 37ЊC in 5% CO 2 in brain-heart infusion (BHI) broth (BioMérieux), on either sheep-blood agar plates (BioMérieux) or tryptic soy agar that contained 5% sheep blood (TSAB; BioMérieux). Ciprofloxacin and moxifloxacin were products of Bayer AG.
The MIC was determined by agar dilution by use of an inoculum of 10 5 -10 6 cfu/mL (this is ∼2-fold higher than the MIC 99 ) [6] . The MPC was determined by applying 0.2 mL of bacterial culture that contained у10 10 cfu/mL to TSAB plates that contained fluoroquinolone at various concentrations. Plates were examined after incubation for 48 and 72 h. The MPC was defined as the lowest fluoroquinolone concentration that prevented bacterial colony formation at 48 h. Identical results were obtained from experiments performed in triplicate.
For animal infection, S. pneumoniae was grown in BHI broth and transferred to agar plates to obtain colonies, of which 25-30 were combined and grown in 9 mL of BHI for 6 h. These cultures were used to form bacterial lawns by incubation on TSAB for 18 h. Lawns were resuspended in physiological saline at a final concentration of 10 10 cfu/mL.
Two silicon catheters (Sigma Medical) were inserted into the jugular vein of immunocompetent rabbits, as described elsewhere [8] . Bacterial pneumonia was induced 24 h after jugular catheterization by endobronchial challenge under laryngoscopic control with 0.5 mL of saline that contained 10 10 cfu/mL S. pneumoniae (the detection of rare mutants requires large inocula). Fluoroquinolone treatment began 4-5 h later through the first central venous catheter at infusion rates controlled by programmable computer software to simulate drug pharmacokinetics in human serum with either (1) [10] .
Rabbits were anesthetized and killed 4-5 h after the last infusion of fluoroquinolone. Each pulmonary lobe was weighed and homogenized in sterile physiological saline. Bacterial numbers were determined by plating 10-fold dilutions of organ homogenates on TSAB, followed by incubation for 24 h. For statistical comparisons of bacterial numbers in lungs, culture-negative lobes were assumed to contain 10 cfu/g tissue, because this was the limit of detection. When bacteria from the pulmonary homogenates grew on TSAB plates that contained fluoroquinolone at 2 and 4 times the initial MIC, additional MIC determinations were made by use of 0.25 mg/L increments in the fluoroquinolone concentration. Nucleotide sequence determination of the quinolone resistance-determining regions (QRDRs) of parC, parE, gyrA, and gyrB [11] was done by use of automated sequencing (Genome Express).
For each animal, the serum concentration of fluoroquinolone was determined by bioassay from blood samples obtained through the second central catheter. A disc agar-plate bioassay method was used with antibiotic medium II (Difco Laboratories) and Escherichia coli NIJJHC2 as the indicator organism. The assay was linear between 0.5 and 7 mg/L ( ); within-day and 2 R p 0.99 between-day coefficients of variation for replicates were !5%. The binding of fluoroquinolone to plasma protein was 30%, as determined by a membrane filtration method [10] . Results were expressed as the free fraction.
For moxifloxacin, doses varied such that the C max was 0.47 ‫ע‬ to mg/L and the AUC 0-24 was to 0.01 22.6 ‫ע‬ 4.3 2.9 ‫ע‬ 0.1 mgh/L. As with humans [10] , no variation in drug 215 ‫ע‬ 24 half-life was associated with the antibiotic dose; thus, a linear 8 5 ϫ 10 pneumoniae/g lung tissue were recovered, of which 1% exhibited an increased MIC (4 mg/L). DNA from 2 of these organisms had nucleotide sequence changes in the QRDR of parC that was expected to change Ser-79 to Phe. A comparable number of bacteria was recovered from 13 control rabbits that had not been given drugs. None of the control animals had bacteria with elevated MICs. Thus, resistant mutants were readily recovered when a wt pneumococcal infection was treated with ciprofloxacin such that serum drug pharmokinetics were equivalent to those attained in human therapy.
Next, 42 rabbits were infected with either wt (16089) or efflux mutant (MS1A) bacteria and then treated with moxifloxacin at doses of 15%-100% of the standard human treatment, once daily for 2 days ( mg/L with wt and 0.25 MIC p MPC p 0.125 mg/L with the efflux mutant). Doses 125% of the standard human treatment reduced bacterial numbers by almost 7 and 6 orders of magnitude with the wt and the efflux strains, respectively (data not shown). Regardless of dose or strain tested, surviving bacteria exhibited no increase in MICs. Thus, 2 doses of moxifloxacin are considerably more effective than are 2 doses of ciprofloxacin at restricting the recovery of S. pneumoniae.
Because in vitro results had predicted that a low-level parC resistance mutation would facilitate the enrichment of resistant gyrase mutants by moxifloxacin [6] , we infected rabbits with the parC mutant strain MR3B4 (moxifloxacin mg/ MIC p 0.25 L; mg/L) and measured mutant enrichment by var-MPC p 4 ious doses of moxifloxacin (6%-600% of the standard human dose). Low doses failed to reduce the bacterial load but did enrich resistant mutants ( figure 1A) , as was seen with ciprofloxacin treatment of wt cells. Doses that were at least twice the simulated human standard were required to reduce the total number of bacteria and fluoroquinolone-resistant mutants (MICу4 mg/L) recovered from rabbit lungs ( figure 1A and 1B,  table 1 ). DNA from 2 of the resistant organisms exhibited alterations in gyrA that are expected to change Ser-81 to Phe in the GyrA protein.
A sharp drop in the recovery of resistant mutants occurred at AUC 0-24 s and MICs of 200-300 ( figure 1A and 1B, averages in table 1). Using classification and regression tree analysis (Answer Tree software; SPSS), the drug exposure (AUC 0-24 /MIC) that limited the recovery of resistant mutants was 300 h ( ), P p .04 a value corresponding to 220% the standard moxifloxacin dose for humans. The recovery of mutants at high moxifloxacin doses dropped sharply as the time below the MPC decreased ( figure 1C, averages in table 1) .
Discussion. The present work establishes that a parC, but not a ciprofloxacin-resistant, efflux mutation in S. pneumoniae facilitates the enrichment of resistant mutants in rabbits treated with moxifloxacin. The results of earlier in vitro studies had shown that the acquisition of a parC fluoroquinolone-resistance mutation by S. pneumoniae decreases susceptibility ∼2-fold for moxifloxacin, increases by 10-fold the selection window for obtaining mutants, increases the frequency at which gyrA mutants are recovered by 3 orders of magnitude, and decreases the lethal activity by 3-fold [6, 7] . These in vivo and in vitro results, together with a surveillance study that reported a prevalence of 4% for parC mutants [12] , suggest a sharp increase in high-level fluoroquinolone resistance and treatment failure [13, 14] if serious efforts are not made to halt the enrichment of additional parC mutants.
The present work also supports the mutant selection-window hypothesis, an idea that provides a rationale for restricting mutant growth [4] -the number of mutants recovered dropped sharply as the time the serum drug concentration exceeded the MPC ( figure 1C) , the upper boundary of the selection window. This drug concentration threshold occurred at AUC 0-24 /MIC p 300. We did not define the lower boundary of the selection window, because resistant mutants were enriched even at the lowest dose, which placed moxifloxacin concentrations above the MIC for 13% of the time.
The ease at which parC resistance mutants were recovered from rabbits after the treatment of wt infection with ciprofloxacin supports the early decision to discourage the use of ciprofloxacin for pneumococcal disease [13] . Levofloxacin, another compound that preferentially enriches parC mutants, is more active, and parC mutants are considered to be susceptible to this drug. However, levofloxacin-resistant parC gyrA double mutants have been readily obtained in vitro [6] , in the rabbit model of pneumonia [8] , and in humans [14] when the infecting strain contains a parC mutation. A key to successful fluoroquinolone use may involve restricting the enrichment of first-step mutants. That may be easier with moxifloxacin than with levofloxacin, because a loss of susceptibility to the former appears first through gyrA mutations, which are recovered less often with moxifloxacin than are parC mutants with levofloxacin [6, 7] .
In summary, when rabbit infection caused by a parC mutant of S. pneumoniae was treated with moxifloxacin at the standard human dose, the drug concentration was below the MPC for 100% of the time, and mutants considered to be resistant were recovered from all of the treated animals. To prevent the same phenomenon from happening in humans when bacterial burdens are high or, perhaps, when patient numbers are very large, efforts must be made to (1) minimize the use of quinolones that readily enrich parC mutants, (2) routinely test S. pneumoniae isolates for parC mutations, and (3) avoid fluoroquinolones when the probability of a parC mutant infection is high, even though such strains may be considered susceptible according to break-point criteria.
